145 related articles for article (PubMed ID: 19041240)
1. Lead identification to generate 3-cyanoquinoline inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment.
Miller LM; Mayer SC; Berger DM; Boschelli DH; Boschelli F; Di L; Du X; Dutia M; Floyd MB; Johnson M; Kenny CH; Krishnamurthy G; Moy F; Petusky S; Tkach D; Torres N; Wu B; Xu W
Bioorg Med Chem Lett; 2009 Jan; 19(1):62-6. PubMed ID: 19041240
[TBL] [Abstract][Full Text] [Related]
2. Lead identification to generate isoquinolinedione inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment.
Mayer SC; Banker AL; Boschelli F; Di L; Johnson M; Kenny CH; Krishnamurthy G; Kutterer K; Moy F; Petusky S; Ravi M; Tkach D; Tsou HR; Xu W
Bioorg Med Chem Lett; 2008 Jun; 18(12):3641-5. PubMed ID: 18501599
[TBL] [Abstract][Full Text] [Related]
3. Discovery and SAR of thiazolidine-2,4-dione analogues as insulin-like growth factor-1 receptor (IGF-1R) inhibitors via hierarchical virtual screening.
Liu X; Xie H; Luo C; Tong L; Wang Y; Peng T; Ding J; Jiang H; Li H
J Med Chem; 2010 Mar; 53(6):2661-5. PubMed ID: 20178321
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitors.
Buchanan JL; Newcomb JR; Carney DP; Chaffee SC; Chai L; Cupples R; Epstein LF; Gallant P; Gu Y; Harmange JC; Hodge K; Houk BE; Huang X; Jona J; Joseph S; Jun HT; Kumar R; Li C; Lu J; Menges T; Morrison MJ; Novak PM; van der Plas S; Radinsky R; Rose PE; Sawant S; Sun JR; Surapaneni S; Turci SM; Xu K; Yanez E; Zhao H; Zhu X
Bioorg Med Chem Lett; 2011 Apr; 21(8):2394-9. PubMed ID: 21414779
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase.
Patnaik S; Stevens KL; Gerding R; Deanda F; Shotwell JB; Tang J; Hamajima T; Nakamura H; Leesnitzer MA; Hassell AM; Shewchuck LM; Kumar R; Lei H; Chamberlain SD
Bioorg Med Chem Lett; 2009 Jun; 19(11):3136-40. PubMed ID: 19394223
[TBL] [Abstract][Full Text] [Related]
6. ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents.
Steiner L; Blum G; Friedmann Y; Levitzki A
Eur J Pharmacol; 2007 May; 562(1-2):1-11. PubMed ID: 17376430
[TBL] [Abstract][Full Text] [Related]
7. Discovery of an inhibitor of insulin-like growth factor 1 receptor activation: implications for cellular potency and selectivity over insulin receptor.
Wood ER; Shewchuk L; Hassel A; Nichols J; Truesdale AT; Smith D; Carter HL; Weaver K; Barrett G; Leesnitzer T; Alvarez E; Bardera AI; Alamillo A; Cantizani J; Martin J; Smith GK; Jensen DE; Xie H; Mook R; Kumar R; Kuntz K
Biochem Pharmacol; 2009 Dec; 78(12):1438-47. PubMed ID: 19665448
[TBL] [Abstract][Full Text] [Related]
8. Biochemical and structural characterization of a novel class of inhibitors of the type 1 insulin-like growth factor and insulin receptor kinases.
Bell IM; Stirdivant SM; Ahern J; Culberson JC; Darke PL; Dinsmore CJ; Drakas RA; Gallicchio SN; Graham SL; Heimbrook DC; Hall DL; Hua J; Kett NR; Kim AS; Kornienko M; Kuo LC; Munshi SK; Quigley AG; Reid JC; Trotter BW; Waxman LH; Williams TM; Zartman CB
Biochemistry; 2005 Jul; 44(27):9430-40. PubMed ID: 15996097
[TBL] [Abstract][Full Text] [Related]
9. SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.
Zimmermann K; Wittman MD; Saulnier MG; Velaparthi U; Sang X; Frennesson DB; Struzynski C; Seitz SP; He L; Carboni JM; Li A; Greer AF; Gottardis M; Attar RM; Yang Z; Balimane P; Discenza LN; Lee FY; Sinz M; Kim S; Vyas D
Bioorg Med Chem Lett; 2010 Mar; 20(5):1744-8. PubMed ID: 20153189
[TBL] [Abstract][Full Text] [Related]
10. The insulin-like growth factor 1 receptor in cancer: old focus, new future.
Hartog H; Wesseling J; Boezen HM; van der Graaf WT
Eur J Cancer; 2007 Sep; 43(13):1895-904. PubMed ID: 17624760
[TBL] [Abstract][Full Text] [Related]
11. Discovery and selectivity-profiling of 4-benzylamino 1-aza-9-oxafluorene derivatives as lead structures for IGF-1R inhibitors.
Krug M; Erlenkamp G; Sippl W; Schächtele C; Totzke F; Hilgeroth A
Bioorg Med Chem Lett; 2010 Dec; 20(23):6915-9. PubMed ID: 21035334
[TBL] [Abstract][Full Text] [Related]
12. The IGF receptor as anticancer treatment target.
Macaulay VM
Novartis Found Symp; 2004; 262():235-43; discussion 243-6, 265-8. PubMed ID: 15562833
[TBL] [Abstract][Full Text] [Related]
13. Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.
Velaparthi U; Liu P; Balasubramanian B; Carboni J; Attar R; Gottardis M; Li A; Greer A; Zoeckler M; Wittman MD; Vyas D
Bioorg Med Chem Lett; 2007 Jun; 17(11):3072-6. PubMed ID: 17398093
[TBL] [Abstract][Full Text] [Related]
14. Discovery and initial SAR of 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-ones as inhibitors of insulin-like growth factor 1-receptor (IGF-1R).
Velaparthi U; Wittman M; Liu P; Stoffan K; Zimmermann K; Sang X; Carboni J; Li A; Attar R; Gottardis M; Greer A; Chang CY; Jacobsen BL; Sack JS; Sun Y; Langley DR; Balasubramanian B; Vyas D
Bioorg Med Chem Lett; 2007 Apr; 17(8):2317-21. PubMed ID: 17317169
[TBL] [Abstract][Full Text] [Related]
15. Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor.
Sekine Y; Furuya Y; Nishii M; Koike H; Matsui H; Suzuki K
Biochem Biophys Res Commun; 2008 Jul; 372(2):356-61. PubMed ID: 18489904
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of insulin-like growth factor-1 receptor tyrosine kinase are preferentially cytotoxic to nutrient-deprived pancreatic cancer cells.
Momose I; Kunimoto S; Osono M; Ikeda D
Biochem Biophys Res Commun; 2009 Feb; 380(1):171-6. PubMed ID: 19166817
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression.
Mukohara T; Shimada H; Ogasawara N; Wanikawa R; Shimomura M; Nakatsura T; Ishii G; Park JO; Jänne PA; Saijo N; Minami H
Cancer Lett; 2009 Sep; 282(1):14-24. PubMed ID: 19345478
[TBL] [Abstract][Full Text] [Related]
18. Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.
Mulvihill MJ; Ji QS; Coate HR; Cooke A; Dong H; Feng L; Foreman K; Rosenfeld-Franklin M; Honda A; Mak G; Mulvihill KM; Nigro AI; O'Connor M; Pirrit C; Steinig AG; Siu K; Stolz KM; Sun Y; Tavares PA; Yao Y; Gibson NW
Bioorg Med Chem; 2008 Feb; 16(3):1359-75. PubMed ID: 17983756
[TBL] [Abstract][Full Text] [Related]
19. The IGF-1 receptor and its contributions to metastatic tumor growth-novel approaches to the inhibition of IGF-1R function.
Bähr C; Groner B
Growth Factors; 2005 Mar; 23(1):1-14. PubMed ID: 16019422
[TBL] [Abstract][Full Text] [Related]
20. 7-Alkoxy-4-phenylamino-3-quinolinecar-bonitriles as dual inhibitors of Src and Abl kinases.
Boschelli DH; Wang YD; Johnson S; Wu B; Ye F; Barrios Sosa AC; Golas JM; Boschelli F
J Med Chem; 2004 Mar; 47(7):1599-601. PubMed ID: 15027848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
